Article

MICS has made very little impact on US and EU surgeon practice

Microincision cataract surgery (MICS), hailed to be the next big development in cataract surgery, has not had the expected impact on surgeon's practice, David Leaming revealed, whilst detailing the results of his most recent survey on cataract surgery practice in Europe and the US.

Microincision cataract surgery (MICS), hailed to be the next big development in cataract surgery, has not had the expected impact on surgeon's practice, David Leaming revealed, whilst detailing the results of his most recent survey on cataract surgery practice in Europe and the US.

Dr Leaming mailed out surveys to all EU members of ESCRS plus members from Bulgaria, Croatia, Norway, Romania, Russia, Switzerland, Turkey, Ukraine and Yugoslavia.

In total 3,083 surveys went out, with 733 returned, 24% response rate. Dr Leaming's analysis included cross comparisons between countries.

He also mailed out surveys to all US ASCRS members not in a training program. Total mail out was 4,645 with 723 returned, a16% response rate, with cross comparisons made for surgical volume.

In Europe, some 14% are doing some MICS, against just 4.4% in the US. Of the Europeans, those half use it in less than 20% of their cases, 13% use it 100% of the time, while 29% see themselves switching to MICS in the next year.

Across Europe, the percentage of surgeons doing LASIK refractive procedures is 28% overall. It's the most popular procedure in Spain, with 89% of surgeons performing it. In Turkey the figure is 68%, France 65%, Greece 57% and Ireland 57%. Phakic IOL implantations are performed by 24% overall, again the highest in Spain with 71%, France 53%, Germany 45%, Turkey 39% and Italy 30%. For Refractive lens exchange (RLE) there were 33% overall, again the highest in Spain with 71%, France 60%, Germany 55% and Italy 45%.

"The results show that there are some practice differences between the US and Europe, and the US leads in some areas while Europe leads in others," said Dr Leaming.

For example, phaco took off in the US a few years before it became common in Europe, while RLE took off in Europe first.

At next year's ASCRS congress, Dr Leaming will present his data along with the data from every other surgical practice survey currently running in Japan, Asia and Australasia in a series of posters. For the first time there will be a snapshot of surgical practice across the world.

Further information, a copy of the survey questionnaires and this year's survey results are all available at www.leamingsurveys.com.

Ophthalmology Times Europe reporting from the XXIV Congress of the ESCRS, London, 9-13 September, 2006.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
© 2025 MJH Life Sciences

All rights reserved.